"Sepsis: Selected Issues in Diagnosis and Treatment" – A New Practical Guide for a Wide Range of Healthcare Professionals
03.05.2018
"Sepsis: Selected Issues in Diagnosis and Treatment" – A New Practical Guide for a Wide Range of Healthcare Professionals
In March 2018, the long-awaited practical guide for physicians, “Sepsis: Selected Issues in Diagnosis and Treatment”, was published by ABV-Press Publishing House. The book was edited by Dr. N.V. Dmitrieva, Professor and Head of the Laboratory for Microbiological Diagnostics and Infection Treatment in Oncology at the N.N. Blokhin National Medical Research Center of Oncology (Ministry of Health of the Russian Federation); Dr. I.N. Petukhova, Senior Researcher at the same laboratory; and Dr. E.G. Gromova, Professor and Head of Intensive Care Unit No. 2 at the N.N. Blokhin National Medical Research Center of Oncology.
Рисунок: http://kraspharma.ru/images/u/cover.gif
This comprehensive guide brings together the most advanced knowledge on the issue of sepsis. It includes chapters on current terminology, diagnostics, and epidemiology of sepsis, while the most critical section provides a detailed overview of therapeutic strategies for managing this severe condition.
The authors emphasize the growing issue of antibiotic resistance among sepsis pathogens and highlight the vital role of microbiological diagnostics in guiding rational therapy choices.
Given that rational sepsis treatment is impossible without effective and safe antimicrobial agents, Section 3 outlines the core principles of therapeutic management. Notably, the authors provide clear clinical recommendations grounded in the principles of evidence-based medicine.
Kraspharma PJSC, a leading Russian manufacturer of modern, effective, and safe hospital-grade antibiotics across various classes, recognizing the medical and social importance of sepsis as a pressing challenge in modern clinical practice, supported the publication of this practical guide.
In acknowledgment of the professionalism and expertise of the authors who contributed to this publication, Kraspharma PJSC proudly presents to the medical community two antimicrobial agents with unique properties—Fosfomycin (powder for solution for intravenous injection) and Sabvixin (INN: Polymyxin B, powder for solution for injection)—designed to combat microbial resistance and enhance the clinical and microbiological effectiveness of sepsis treatment.
We present Chapter 3.1 of the practical guide, dedicated to antimicrobial therapy for sepsis.
Рисунок: http://kraspharma.ru/images/u/cover.gif
This comprehensive guide brings together the most advanced knowledge on the issue of sepsis. It includes chapters on current terminology, diagnostics, and epidemiology of sepsis, while the most critical section provides a detailed overview of therapeutic strategies for managing this severe condition.
The authors emphasize the growing issue of antibiotic resistance among sepsis pathogens and highlight the vital role of microbiological diagnostics in guiding rational therapy choices.
Given that rational sepsis treatment is impossible without effective and safe antimicrobial agents, Section 3 outlines the core principles of therapeutic management. Notably, the authors provide clear clinical recommendations grounded in the principles of evidence-based medicine.
Kraspharma PJSC, a leading Russian manufacturer of modern, effective, and safe hospital-grade antibiotics across various classes, recognizing the medical and social importance of sepsis as a pressing challenge in modern clinical practice, supported the publication of this practical guide.
In acknowledgment of the professionalism and expertise of the authors who contributed to this publication, Kraspharma PJSC proudly presents to the medical community two antimicrobial agents with unique properties—Fosfomycin (powder for solution for intravenous injection) and Sabvixin (INN: Polymyxin B, powder for solution for injection)—designed to combat microbial resistance and enhance the clinical and microbiological effectiveness of sepsis treatment.
We present Chapter 3.1 of the practical guide, dedicated to antimicrobial therapy for sepsis.
